GLGill Lawrence

Gill Lawrence

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Gill Lawrence has a total of 54 co-authors. Here are the top co-authors by number of shared publications:

  • Olive Kearins

    National Lead Breast Screening QA, Public Health England, Birmingham, UK

    4 shared publications
  • Emma O'SUllivan

    QA Information & Development Manager, West Midlands Breast Screening QA Reference Centre, West Midlands Cancer Intelligence Unit, Public Health Building, The University of Birmingham, Birmingham B15 2TT, UK

    2 shared publications
  • Matthew Wallis

    Department of Radiology, Addenbrooke's Hospital, Cambridge, United Kingdom

    2 shared publications
  • Adele Francis

    University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom

    1 shared publication
  • Alastair Mark Thompson

    The University of Texas MD Anderson Cancer Center, Houston, TX

    1 shared publication
  • Amy Downing

    Leeds Institute of Medical Research at St James's and Leeds Institute for Data Analytics, University of Leeds, Leeds, UK

    1 shared publication

Latest Publications

  • Treatment and outcomes from a large, prospective, national longitudinal cohort study of screen detected ductal carcinoma in situ (DCIS).

    by Alastair Mark Thompson, Graham Ball, Karen Clements, Matthew Wallis, Jeremy Thomas, Anthony Maxwell, Gill Lawrence, Adele Francis, Andrew Hanby, Maggie Wilcox, et al.

    1570 Background: The degree of over-diagnosis and over-treatment for ductal carcinoma in situ (DCIS) remains contentious. Hypotheses from retrospective data were tested in a prospective, population-based study. Methods: A prospective longitudinal cohort of 12,838 women diagnosed through a population-based national breast screening program accrued 2003-2012 with proforma for imaging, surgery, pathology and adjuvant therapy. Follow-up was linked to national databases and case note review to analyse patterns of care, recurrence and mortality. Results: Data was complete for 9,972/12,838 (78%) women (mean age 60 years; range 46-87) with median follow up 62 months (range 6-116). Breast conservation (BCS) was definitive surgery for 7,028 (70.5%) women; use increased with older age (CHI2 380, 6 df p < 0.001). Mastectomy (Mx; n = 2,944) was associated with higher grade DCIS (CHI2 19.31, 2 df P < 0.001), larger size (CHI2 203.9, 5 df P < 0.001) and comedo necrosis (CHI2 9.1, 1 df P = 0.003). For patients undergoing BCS, use of radiotherapy was associated with high grade (CHI2 199.9, 2 df P < 0.001), comedo necrosis (CHI2 62.3, 1 df P = 0.001), larger size (CHI2 57.5, 5 df P < 0.001), microinvasion (CHI2 49.9, 1 df P = < 0.001), and use of endocrine therapy (CHI2 16.47, 3 df P < 0.001), but not close ( < 1mm) or involved margin(s). In women who underwent BCS, ipsilateral in-breast recurrence (n = 368; CHI2 27.14, 5 df P < 0.001) and ipsilateral invasive cancer (n = 182; CHI2 32.62, 5 df P < 0.001) were significantly reduced by radiotherapy, independent of margins. Endocrine therapy reduced local recurrence by 1.52%, independent of radiotherapy. Among 324 deaths (3.3% of the cohort), 47 were from invasive breast cancer. There was no difference in overall mortality by type of surgery (3.16% BCS vs 3.5% Mx; CHI2 0.017, 3 1f, P = 0.90), use of radiotherapy (2.48% or not 3.84%; CHI2 0.30, 1 df, P = 0.59) or endocrine therapy (3.88% or not 3.14%; CHI2 0.077, 1 df, P = 0.78). Conclusions: This prospective cohort of contemporary, screen-detected DCIS demonstrates ipsilateral recurrence, but not mortality, is reduced by radiotherapy and endocrine therapy. Death due to breast cancer was rare, outnumbered 5:1 by death from other causes.


  • Open Access

    Use of name recognition software, census data and multiple imputation to predict missing data on ethnicity: application to cancer registry records

    by Ronan Ryan, Sally Vernon, Gill Lawrence, Sue Wilson

    Information on ethnicity is commonly used by health services and researchers to plan services, ensure equality of access, and for epidemiological studies. In common with other important demographic and clinical data it is often incompletely recorded. This paper presents a method for imputing missing data on the ethnicity of cancer patients, developed for a regional cancer registry in the UK.


  • Are symptomatic guidelines for chemotherapy appropriate to ER-positive screen-detected breast cancer (SDBC)?

    by Nigel J. Bundred, Ramachandran Prasad, Julie Morris, W. Fiona Knox, Ged Byrne, Shan Cheung, Mary Wilson, Gill Lawrence

    Oncologists recommend chemotherapy to postmenopausal women with adverse prognostic factors, but predictors of the benefit of chemotherapy are mainly based on mortality from symptomatic cancer trials. From 1990 to 1998, 1475 breast cancers (875 screen detected cancers [SDBCs]: 600 symptomatic) were treated in women aged 50–65 years and prognostic factors compared with cancer mortality. Median follow-up was 110 months. The Nottingham Prognostic Index (NPI) was calculated for 6737 breast cancers which were part of the Association of Breast Surgery (ABS) 2001/2002 Audit of SDBCs to validate survival figures. Ten year survival was 92.1% for SDBC and 77.6% for symptomatic cancers. Adjusting for baseline factors, SDBCs had a reduced mortality (RR = 0.42 (0.31–0.57), independent of grade, node status and tumour size. Oestrogen receptor (ER) positive SDBC had a lower annual mortality rate (0.6%) compared with symptomatic (4.3%: P < 0.001) or ER negative SDBC (1.8%). Epithelial proliferation was lower in SDBC in all NPI groups compared with symptomatic cancers (P ≤ 0.001). Grade, node status, ER status, size and mode of detection predicted survival. Survival for each NPI group was better for SDBC. For ER positive SDBC in the Moderate Prognostic Group 1 (MPG1), 10 year mortality was 6.4% compared with 17.6% in symptomatic (P = 0.001). NPI on 6,737 operable SDBC confirmed similar mortality in all groups (4% mortality in MPG1 group). SDBC have lower mortality than symptomatic due to a lower proliferative index. The use of adjuvant chemotherapy is over-treatment for ER positive SDBCs with Good Prognostic Group (GPG) and MPG1 NPI scores.


  • Open Access

    PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer

    by Gordon C Wishart, Elizabeth M Azzato, David C Greenberg, Jem Rashbass, Olive Kearins, Gill Lawrence, Carlos Caldas, Paul Dp Pharoah

    Introduction: The aim of this study was to develop and validate a prognostication model to predict overall and breast cancer specific survival for women treated for early breast cancer in the UK. Methods: Using the Eastern Cancer Registration and Information Centre (ECRIC) dataset, information was collated for 5,694 women who had surgery for invasive breast cancer in East Anglia from 1999 to 2003. Breast cancer mortality models for oestrogen receptor (ER) positive and ER negative tumours were derived from these data using Cox proportional hazards, adjusting for prognostic factors and mode of cancer detection (symptomatic versus screen-detected). An external dataset of 5,468 patients from the West Midlands Cancer Intelligence Unit (WMCIU) was used for validation. Results: Differences in overall actual and predicted mortality were <1% at eight years for ECRIC (18.9% vs. 19.0%) and WMCIU (17.5% vs. 18.3%) with area under receiver-operator-characteristic curves (AUC) of 0.81 and 0.79 respectively. Differences in breast cancer specific actual and predicted mortality were <1% at eight years for ECRIC (12.9% vs. 13.5%) and <1.5% at eight years for WMCIU (12.2% vs. 13.6%) with AUC of 0.84 and 0.82 respectively. Model calibration was good for both ER positive and negative models although the ER positive model provided better discrimination (AUC 0.82) than ER negative (AUC 0.75). Conclusions: We have developed a prognostication model for early breast cancer based on UK cancer registry data that predicts breast cancer survival following surgery for invasive breast cancer and includes mode of detection for the first time. The model is well calibrated, provides a high degree of discrimination and has been validated in a second UK patient cohort.


  • Open Access

    Screening histories of invasive breast cancers diagnosed 1989–2006 in the West Midlands, UK: variation with time and impact on 10-year survival

    by Gill Lawrence, Emma O'SUllivan, Olive Kearins, Nancy Tappenden, Kate Martin, Matthew Wallis

    Objectives: To examine variations in screening status category with time for 20,862 invasive breast cancers diagnosed in the West Midlands between 1989 and 2006, and to provide 10-year relative survival rates for each category. Method: Population-based breast screening was introduced in the West Midlands from 1988. Primary invasive breast cancers diagnosed from 1 April 1989 to 31 March 2006 in women eligible for breast screening were identified from the West Midlands Cancer Intelligence Unit's cancer registration database. A screening status was determined for each case using previously published methodology. Results: Screening status rates are affected initially by the gradual rollout of the screening programme and more recently by the need to wait for three years before interval cancers and cancers in lapsed and non-attenders can be identified. In the steady-state period 1994–2003, 40.6% of invasive breast cancers were screen-detected, 36.3% were interval cancers and 11.2% were cancers in non-attenders (NA). Ten-year relative survival was 89.6% for screen-detected breast cancers, 73.3% for interval cancers and 51.9% for cancers in NA. Conclusion: The detection of invasive breast cancers by screening has improved over time, with an equivalent reduction in the numbers of interval cancers. This, together with a stable rate of cancers in NA and an improvement in the survival of women with interval cancers, suggests that further improvements in breast cancer mortality can be predicted. International comparisons of interval cancer rates are difficult due to interprogramme differences in the time between screens.


  • Survivorship experience of West Midlands breast cancer patients who died in 2005-07

    by Gill Lawrence, J. Walton, E. O'Sullivan, M. Porter, C. Mellors, O. Kearins

  • Open Access

    Changes in and predictors of length of stay in hospital after surgery for breast cancer between 1997/98 and 2004/05 in two regions of England: a population-based study

    by Amy Downing, Mark Lansdown, Robert M West, James D Thomas, Gill Lawrence, David Forman

    Decreases in length of stay (LOS) in hospital after breast cancer surgery can be partly attributed to the change to less radical surgery, but many other factors are operating at the patient, surgeon and hospital levels. This study aimed to describe the changes in and predictors of length of stay (LOS) in hospital after surgery for breast cancer between 1997/98 and 2004/05 in two regions of England.


  • Open Access

    Invitation Management Initiative to Improve Uptake of Breast Cancer Screening in an Urban Uk Primary Care Trust

    by Olive Kearins, Jackie Walton, Emma O'SUllivan, Gill Lawrence

    Objectives: In an attempt to improve breast cancer screening uptake and coverage, persistent non-offenders in the Heart of Birmingham Teaching Primary Care Trust were included in an invitation management initiative. Methods: Persistent non-attenders were identified in routine screening lists. Phone contact was attempted or a home visit was made. If the case was not resolved, a second appointment was made and further phone calls and home visits were attempted. Results: Of 548 persistent non-attenders identified, 228 (42%) declined screening, 171 (31%) attended, 72 (13%) had moved away or died, 11 (2%) were recently screened or under care for other conditions. Sixty-six cases (12%) remained unresolved. Fourteen women opted to be permanently withdrawn from the National Health Service Breast Screening Programme (NHSBSP). Twenty-four women had a negative experience of breast cancer screening (defaulted, recalled for assessment, recalled for technical reasons). No malignancies were found. A total of 1375 phone calls and 230 home visits were attempted. Uptake would have been 62.2% if none of the persistent non-attenders included in the initiative had attended for screening. With the initiative, uptake of breast cancer screening was increased to 65.3%. Conclusions: Phone calls and home visits resulted in only a moderate increase in breast cancer screening uptake. The initiative encouraged nervous attenders who were reassured about the screening process. However, more women declined screening than were screened and the initiative made it easier for women to request to be permanently withdrawn from the NHSBSP.


  • Open Access

    The use of cervical screening history data to interpret cervical cancer incidence trends

    by Joanne Clare, Diane Edwards, Helen Bagnall, Philippa Pearmain, Gill Lawrence

    Regional Cervical Screening Quality Assurance Reference Centres maintain and improve the quality of their local cervical screening programmes by monitoring standards based on a range of outcome measures. The classification of invasive cervical cancer screening histories can aid the interpretation of cervical cancer incidence trends in cervical screening services. Cervical cancer incidence rates were calculated for cytology laboratory catchment areas, which reflected where local general practitioners sent cervical samples. After reviewing changes in invasive cervical cancer incidence rates in the West Midlands during the period 1988–2004 to identify unusual trends, a detailed retrospective screening history analysis was carried out for one local screening service. An upward trend in invasive cervical cancer incidence in one laboratory catchment area was caused by an increase in cases occurring in women who had not been routinely screened. Quality assurance data provided supporting evidence for non-attendance at screening during this time. Assigning a screening status to invasive cervical cancers provides valuable information through which to understand the reasons for changes in cancer incidence with time in local screening services. These data can be used to identify areas of potential concern, thereby facilitating quality assurance activities.